



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/779,791	02/08/2001	Jon A. Wolff	Mirus.006.03	Mirus.006.03 6737	
25032	7590 10/04/	5	EXAMINER		
	RPORATION	WOITACH, JOSEPH T			
505 SOUTH MADISON,			ART UNIT	PAPER NUMBER	
			1632		

DATE MAILED: 10/04/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
		09/779,791	WOLFF ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Joseph T. Woitach	1632				
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	correspondence address	**			
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATE in a sions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It is period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin vill apply and will expire SIX (6) MONTHS from 1, cause the application to become ABANDONE	N. nely filed the mailing date of this communic D (35 U.S.C. § 133).				
Status							
1)🛛	Responsive to communication(s) filed on 30 Ju	ine 2005					
2a)□	and the second s	action is non-final.					
3)	Since this application is in condition for allowar		osecution as to the merit	s is			
,—	closed in accordance with the practice under E	•		0 10			
Dispositi	on of Claims						
4)⊠	Claim(s) 1-6 and 13 is/are pending in the applic	cation					
	4a) Of the above claim(s) is/are withdrawn from consideration.						
	Claim(s) is/are allowed.						
·	Claim(s) <u>1-6 and 13</u> is/are rejected.						
7)							
·	Claim(s) are subject to restriction and/or	r election requirement					
•	on Papers	·		·			
	•						
-	The specification is objected to by the Examine		_				
10)	The drawing(s) filed on is/are: a)□ acce	•					
	Applicant may not request that any objection to the		· · · .				
	Replacement drawing sheet(s) including the correcti			• •			
11)	The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152	2.			
Priority ι	ınder 35 U.S.C. § 119						
a)[	Acknowledgment is made of a claim for foreign  All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau see the attached detailed Office action for a list of	s have been received. s have been received in Applicati ity documents have been receive (PCT Rule 17.2(a)).	on No ed in this National Stage				
	:	or the certified copies flot receive	.u.				
Attachment	• •						
	e of References Cited (PTO-892)	4) Interview Summary					
3) 🔲 Inforn	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date	Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate Patent Application (PTO-152)				

Art Unit: 1632

### Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on June 30, 2005 has been entered.

### **DETAILED ACTION**

This application filed February 8, 2001, is a continuation in part of application 09/312,351, filed May 14, 1999.

Applicants' amendment filed June 30, 2005, has been received and entered. Claims 7-12 have been canceled. Claim 1 has been amended. Claims 1-6 and 13 are pending and currently under examination.

### Election/Restriction

As noted in previously, Groups I and II have been rejoined.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1 48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

Art Unit: 1632

application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## Claim Rejections - 35 USC 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-6 and 13 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. 37 CFR 1.118 (a) states that "No amendment shall introduce new matter into the disclosure of an application after the filing date of the application". Specifically, the recitation of "eliminates subsequent transport of said molecule across said membrane by the transduction signal" is considered new matter.

Initially, it is noted that the basis of the previous rejection has been obviated by the amendment to the claims to delete the terminology subject to the rejection. Applicants have pointed to various portions of the present specification for support of the instantly claimed amendment. Review of the portions of the specification and Applicants' summary of the embodiments are acknowledged. However, none of the cited passages, nor the specification as a whole provide literal support for the new amendment.

It is acknowledged that pages 25-26 provide guidance for contemplated retention signals, and Example 10 (pages 38-39) provides one example where a TAT conjugated fluorophore was

tested by pulse chase experiments. At each of the cited portions of the specification there is no literal support for the claimed activity. It is noted that Example 10 provides a comparison of other covalent linkages and that under specific conditions reveals that a fluorophore is detected for a longer period of time when it is provided to the cell as an activated disulfide 4-aminophenyl disulphide, however provides no specific basis or discussion on the importance of the specific bond or the claimed functional bond in general. The basis of the rejection focuses on the fact that the specification provides no literal support for the claimed amendment.

To the extent that the claimed compositions and/or methods are not described in the instant disclosure, claims 1-6 and 13 are also rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention, since a disclosure cannot teach one to make or use something that has not been described.

MPEP 2163.06 notes "If new matter is added to the claims, the examiner should reject the claims under 35 U.S.C. 112, first paragraph - written description requirement. In re Rasmussen, 650 F.2d 1212, 211 USPQ 323 (CCPA 1981)." MPEP 2163.02 teaches that "Whenever the issue arises, the fundamental factual inquiry is whether a claim defines an invention that is clearly conveyed to those skilled in the art at the time the application was filed...If a claim is amended to include subject matter, limitations, or terminology not present in the application as filed, involving a departure from, addition to, or deletion from the disclosure of the application as filed, the examiner should conclude that the claimed subject matter is not described in that application. MPEP 2163.06 further notes "When an amendment is filed in reply to an objection

Art Unit: 1632

or rejection based on 35 U.S.C. 112, first paragraph, a study of the entire application is often necessary to determine whether or not "new matter" is involved. Applicant should therefore specifically point out the support for any amendments made to the disclosure".

### Conclusion

No claim is allowed.

The art teaches that chemically linking molecules to proteins such as TAT allow for better in vivo uptake of molecules (for example Lee et al. Bioconjugate Chem 2001 12:995-999, and Moulton et al. Drug Discovery Today 9(20):870), and at the time of filing that other types of proteins conjugated to polynucleotides were being tested (see for example Kang et al. Drug Metab Dispos. 1995 Jan;23(1):55-9). However, the claims are free of the art of record because the art fails to teach compounds with the structural and functional properties of those instantly claimed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Woitach whose telephone number is (571) 272-0739.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached at (571) 272-0735.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group analyst Dianiece Jacobs whose telephone number is (571) 272-0532.

Joseph T. Woitach

() al Wortene)